Our findings suggest that decreasing IL-1Racp, with relevance to pharmaceutical interventions, might reduce the risk of lung cancer in the general population, perhaps via other IL-1 family members/receptors, especially IL-1α/β and IL-1Ra. This evidence concerns the gene IL1A and lung carcinoma.